Leads Biolabs’ Opamtistomig Becomes World’s First 4-1BB Bispecific Antibody to Enter Pivotal Phase III for EP-NEC

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced it has received regulatory clearance in China to initiate a Phase III clinical study evaluating opamtistomig (LBL-024) in combination with platinum chemotherapy for patients with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC). The bispecific antibody represents the world’s first molecule targeting the co-stimulatory receptor 4-1BB to advance to a single-arm pivotal clinical stage, leveraging Leads Biolabs’ proprietary X-body technology platform.

Clinical Development Milestone

Drug Profile & Innovative Mechanism

Opamtistomig (LBL-024) represents a breakthrough bispecific antibody design:

• Targets: Dual targeting of PD-L1 and 4-1BB co-stimulatory receptor
• Structure: 2:2 structural design enabling simultaneous engagement of both targets
• Mechanism: Relieves PD-1/PD-L1-mediated immunosuppression while enhancing 4-1BB-modulated T-cell activation
• Synergistic Effect: Dual action achieves potent anti-tumor activity exceeding monotherapy approaches

Proprietary Technology Platform

The drug is developed using Leads Biolabs’ patented X-body technology platform:

• Platform Innovation: Enables precise engineering of complex bispecific antibody architectures
• Structural Control: 2:2 design ensures optimal target engagement and signaling modulation
• Safety Optimization: Platform designed to minimize cytokine release syndrome risks associated with 4-1BB agonists
• Manufacturing Capability: Demonstrates Leads Biolabs’ ability to produce complex biologics at commercial scale

Market Opportunity & Unmet Need

• EP-NEC Burden: Rare but aggressive cancer with limited treatment options and poor prognosis
• Current Standard: Platinum-based chemotherapy provides modest benefit with median survival of 8-12 months
• Immunotherapy Gap: PD-1/PD-L1 inhibitors show limited efficacy in neuroendocrine carcinomas
• Commercial Potential: Orphan disease designation supports premium pricing and accelerated regulatory pathways

Competitive Differentiation

• First-Mover Advantage: World’s first 4-1BB bispecific in pivotal trials creates substantial competitive moat
• Safety Profile: Bispecific design potentially avoids systemic 4-1BB activation toxicity seen with monospecific agonists
• Broader Applicability: Mechanism suggests potential expansion beyond EP-NEC to other immune-cold tumors
• Platform Validation: Success validates X-body platform for additional bispecific candidates in pipeline

Strategic Implications for Leads Biolabs

• Global Leadership: Establishes Leads Biolabs as pioneer in 4-1BB bispecific antibody development
• Pipeline De-risking: Pivotal trial success could support accelerated approval and rapid commercial launch
• Partnership Value: Strong clinical data likely to attract global pharmaceutical partnership interest
• Valuation Catalyst: First-in-class status in high-value immuno-oncology space supports significant valuation upside

Development Timeline & Regulatory Strategy

• Phase III Initiation: Expected to begin Q3-Q4 2026 with rapid enrollment due to single-arm design
• Primary Endpoint: Likely objective response rate (ORR) or progression-free survival (PFS)
• Accelerated Pathway: Single-arm pivotal design suggests pursuit of conditional/accelerated approval
• Global Expansion: Success in China likely to support parallel FDA/EMA filings

Broader Therapeutic Potential

While initially focused on EP-NEC, opamtistomig’s mechanism suggests applicability across multiple tumor types:

• Immune-Cold Tumors: Tumors resistant to current checkpoint inhibitors may respond to dual PD-L1/4-1BB approach
• Combination Opportunities: Potential synergy with chemotherapy, radiation, or other immunotherapies
• Biomarker Development: PD-L1 expression and 4-1BB presence may guide patient selection
• Platform Extension: X-body technology enables rapid development of additional bispecific combinations

Investment Considerations

• Risk-Reward Profile: Pivotal trial represents major value inflection point with binary outcome
• Market Timing: 4-1BB field heating up with multiple companies pursuing different approaches
• Manufacturing Readiness: Complex bispecific production requires sophisticated capabilities already demonstrated
• Intellectual Property: Patented X-body platform provides strong protection against competitors

Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial expectations for opamtistomig. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption patterns.-Fineline Info & Tech